{"id":14004,"date":"2021-07-29T12:29:06","date_gmt":"2021-07-29T10:29:06","guid":{"rendered":"http:\/\/miunidad.eu\/porib.com\/?p=14004"},"modified":"2021-07-29T12:29:54","modified_gmt":"2021-07-29T10:29:54","slug":"mareque-m-montesinos-p-font-p-guinea-jm-de-la-fuente-a-soto-j-oyaguez-i-brockbank-j-iglesias-t-llinares-j-sierra-j","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/mareque-m-montesinos-p-font-p-guinea-jm-de-la-fuente-a-soto-j-oyaguez-i-brockbank-j-iglesias-t-llinares-j-sierra-j\/","title":{"rendered":"Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyag\u00fcez I, Brockbank J, Iglesias T, Llinares J, Sierra J"},"content":{"rendered":"<div class=\"miniatura_foto\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-13677 alignleft\" src=\"https:\/\/porib.com\/wp-content\/uploads\/2021\/07\/clinicoeconomics_and_outcomes_research.jpg\" alt=\"\" width=\"90\" height=\"120\" \/><\/div>\n<p style=\"text-align: justify;\"><strong>Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyag\u00fcez I, Brockbank J, Iglesias T, Llinares J, Sierra J<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h6 style=\"text-align: justify;\">Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with CD-33 positive acute myeloid leukaemia in Spain<\/h6>\n<h6 style=\"text-align: justify;\"><strong>ClinicoEconomics and Outcomes Research 2021; 13:263-277<\/strong><\/h6>\n<div class=\"col80p\">\n<p style=\"text-align: justify;\"><a href=\"https:\/\/www.dovepress.com\/cost-effectiveness-analysis-of-gemtuzumab-ozogamicin-for-first-line-tr-peer-reviewed-fulltext-article-CEOR\" target=\"_blank\" rel=\"noopener\">M\u00c1S INFORMACI\u00d3N<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyag\u00fcez I, Brockbank J, Iglesias T, Llinares J, Sierra J &nbsp; &nbsp; Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with CD-33 positive acute myeloid leukaemia in Spain ClinicoEconomics and Outcomes Research 2021; 13:263-277 M\u00c1S INFORMACI\u00d3N<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"quote","meta":{"footnotes":""},"categories":[116,933,336],"tags":[],"class_list":["post-14004","post","type-post","status-publish","format-quote","hentry","category-ace-acu-tipo-de-proyecto","category-hematologia-oncohematologia","category-clinicoeconomics-and-outcomes-research","post_format-post-format-quote"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14004"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=14004"}],"version-history":[{"count":3,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14004\/revisions"}],"predecessor-version":[{"id":14007,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14004\/revisions\/14007"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=14004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=14004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=14004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}